FDA has approved a dry powder inhaler, treprostinil, under the brand name Tyvaso DPI from United Therapeutics. The drug is for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.

United Therapeutics' GAAP net income for 3 months of 2022 was $239.9 million, up 8.5 times from $28.3 million in the previous year. Revenue increased by 19.2% to $451.9 million compared to $379.1 million a year earlier.

United Therapeutics' GAAP net income for 2021 was $475.8 million, down 7.6% from $514.8 million in the previous year. Revenues increased 13.7% to $1.686 billion from $1.483 billion a year earlier.

United Therapeutics' GAAP net income for 9M 2021 was $363.6 million, down 12.6% from $416 million in the previous year. Revenue increased 15.7% to $1.27 billion compared to $1.098 billion a year earlier.